CurrentUnitedHealthcarePolicy 2026 P 1152-14

Cosentyx (secukinumab) prior authorization

UnitedHealthcare prior authorization/notification policy for Cosentyx (secukinumab) prefilled syringe or Sensoready pen, defining initial and reauthorization clinical criteria for multiple labeled indications and program operational notes. Effective for the payer's commercial utilization management processes.

Policy Summary

PayerUnitedHealthcare

PolicyCosentyx (secukinumab) prior authorization

Policy CodePolicy 2026 P 1152-14

Change TypeAnnual review (clarified); Added HS (2024)

Effective DateApr 1, 2026

Next Review Date

Key ActionPrior authorization/notification is required for Cosentyx; authorization is issued for 12 months for approved requests.

POLICY UPDATE CHANGES

1/2026 annual review updated 'not used in combination' verbiage and examples with no change to clinical intent.

1/2024 added coverage criteria for new indication for Hidradenitis Suppurativa (HS).

8Indications with explicit criteria (plaque psoriasis, PsA, AS, nr-axSpA, ERA, HS)

12Authorization duration (months)

2015-2026Policy review history range

Coverage Summary

UnitedHealthcare covers Cosentyx (secukinumab) prefilled syringe or Sensoready pen under a prior authorization/notification program (Policy/Program Number 2026 P 1152-14) for labeled indications including plaque psoriasis, psoriatic arthritis (PsA), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), enthesitis-related arthritis (ERA), and hidradenitis suppurativa (HS). Coverage is provided with specific clinical criteria for initial authorization and reauthorization across these indications.